Eyeworld Supplements

ASCRS Clinical Survey 2022

This is a supplement to EyeWorld Magazine.

Issue link: https://supplements.eyeworld.org/i/1483249

Contents of this Issue

Navigation

Page 6 of 7

2022 ASCRS CLINICAL SURVEY | 7 Based on those currently performing presbyopia-correcting IOLs (80%) n=753 In patients implanted with a multifocal or extended depth of focus IOL, how much spherical deviation from your intended target do you consider to be visually significant (i.e., likely to have an impact on visual quality and patient satisfaction) in diopters? ≥0.25 D and ≤0.50 D >0.50 D and ≤0.75 D >0.75 D and ≤1.0 D >1.0 D and ≤1.25 D >1.25 D and ≤1.5 D 3% 0% 9% 43% 45% Intended target is ≥0.50 D and ≤0.75 D by segment 2022 Practice location U.S. 47% International 41% Years in practice Early stage (0–5years) 38% Mid stage (6–10 years) 46% Last stage (11+ years) 47% Perform majority of surgeries in Hospital outpatient department (HOPD) 42% Office 39% Gender Male 45% Female 45% What percentage of all cataract cases do you plan for "true" monovision, instead of performing a presbyopia IOL procedure? (with a 1.0 D difference or greater between eyes aer surgery)? Average % of cataract cases planned for "true" monovision by segment 2022 Practice location U.S. 9% International 9% Years in practice Early stage (0–5years) 9% Mid stage (6–10 years) 8% Last stage (11+ years) 9% Perform majority of surgeries in Hospital outpatient department (HOPD) 8% Office 9% Gender Male 9% Female 9% None <5% 5–15% 16–25% >25% 11% 7% 34% 4% 44% average cataract cases planned for "true" monovision with a ≥1.0 D difference 9% Based on those currently performing presbyopia-correcting IOLs (80%) n=753

Articles in this issue

Archives of this issue

view archives of Eyeworld Supplements - ASCRS Clinical Survey 2022